Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology
Authors:
- Stefania CrisciSCStefania Crisci
- Filomena AmitranoFAFilomena Amitrano
- Mariangela SaggeseMSMariangela Saggese
- Tommaso MutoTMTommaso Muto
- Sabrina SarnoSSSabrina Sarno
- Sara MeleSMSara Mele
- Pasquale VitalePVPasquale Vitale
- Giuseppina RongaGRGiuseppina Ronga
- Massimiliano BerrettaMBMassimiliano Berretta
- Raffaele Di FranciaRFRaffaele Di Francia
Open Access
Abstract
The upgraded knowledge of tumor biology and microenviroment provides information on differences in neoplastic and normal cells. Thus, the need to target these differences led to the development of novel molecules (targeted therapy) active against the neoplastic cells’ inner workings. There are several types of targeted agents, including Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA (iRNA) molecules and microRNA. In the clinical practice, these new medicines generate a multilayered step in pharmacokinetics (PK), which encompasses a broad individual PK variability, and unpredictable outcomes according to the pharmacogenetics (PG) profile of the patient (e.g., cytochrome P450 enzyme), and to patient characteristics such as adherence to treatment and environmental factors. This review focuses on the use of targeted agents in-human phase I/II/III clinical trials in cancer-hematology. Thus, it outlines the up-to-date anticancer drugs suitable for targeted therapies and the most recent finding in pharmacogenomics related to drug response. Besides, a summary assessment of the genotyping costs has been discussed. Targeted therapy seems to be an effective and less toxic therapeutic approach in onco-hematology. The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy. This could allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.Keywords
This publication has 131 references indexed in Scilit:
- Comprehensive review of JAK inhibitors in myeloproliferative neoplasmsTherapeutic Advances in Hematology, 2012
- Hedgehog pathway as a drug target: Smoothened inhibitors in developmentOncoTargets and Therapy, 2012
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2011
- Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline ChemotherapyIn vivoin Human Acute Myeloid Leukemia ModelsMolecular Cancer Therapeutics, 2010
- Expression of the Brain Transcription Factor OTX1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive Non-Hodgkin LymphomaThe American Journal of Pathology, 2009
- Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin LymphomaClinical Cancer Research, 2009
- In vitroandIn vivoCharacterization of MDX-1401 for Therapy of Malignant LymphomaClinical Cancer Research, 2009
- Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome–positive leukemiaBlood, 2009
- Ferritin >1000: grand for hemochromatosis screening?Blood, 2008
- A review of tositumomab and I131tositumomab radioimmunotherapy for the treatment of follicular lymphomaExpert Opinion on Biological Therapy, 2005